We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    ct011 hcv
Previous Study | Return to List | Next Study

Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00962936
First Posted: August 20, 2009
Last Update Posted: August 29, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Teva Pharmaceutical Industries
Information provided by (Responsible Party):
CureTech Ltd
August 19, 2009
August 20, 2009
August 29, 2014
September 2009
October 2011   (Final data collection date for primary outcome measure)
To assess the safety and tolerability of CT-011 in patients with Chronic Hepatitis C due to HCV Genotype I infection [ Time Frame: 12 months ]
Same as current
Complete list of historical versions of study NCT00962936 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection
Phase I/II Study to Evaluate the Safety and Tolerability of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection
This study aims to evaluate whether an investigational monoclonal antibody, CT-011, is safe to give and if it helps patients with hepatitis C virus (HCV). Monoclonal antibodies are a type of drug that is typically given by infusion into a vein (intravenously). Results of this trial will help doctors obtain additional information with regard to the safety and efficacy of CT-011 as a potential treatment for HCV.
Not Provided
Interventional
Phase 1
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Chronic Hepatitis C
Drug: CT-011
CT-011
Experimental: CT-011
Intervention: Drug: CT-011
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
13
January 2013
October 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patient is between 18 and 60 years of age, both genders.
  2. Biopsy proven infection with Hepatitis C genotype 1.
  3. Positive for anti-HCV.
  4. Chronically infected for at least 3 months from diagnosis.
  5. ECOG performance status ≤ 1.
  6. Previous therapy with interferon +/- Ribavirin or Peginterferon +/- Ribavirin or ineligibility for this type of therapy or for liver transplantation.

Exclusion Criteria:

  1. Patients who received any type of anti viral treatment during the 3 months prior to enrollment.
  2. Any history or active malignancy.
  3. History of major organ transplantation with an existing functional graft.
  4. Patients who received any systemic concurrent therapy within the last 4 weeks.
  5. Patients progressing to acute liver failure (ALF).
Sexes Eligible for Study: All
18 Years to 60 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Israel
 
 
NCT00962936
CT-2009-01
No
Not Provided
Not Provided
CureTech Ltd
CureTech Ltd
Teva Pharmaceutical Industries
Principal Investigator: Yaron Ilan, MD Hadassah Medical Center
CureTech Ltd
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP